Acute myeloid leukemia · 4 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Busulfan and Fludarabine, then allo HSCT Variant #08 Partial | — | R 30 308 | — | ~9.0 mo | — | ~1 | ~R 30 308 PFS proxy · indirect | 2 |
Busulfan and Cyclophosphamide, then allo HSCT Variant #02 Partial | — | R 13 162 | — | — | — | 1 | R 13 162 PFS proxy | 1 |
Clofarabine and Melphalan, then allo HSCT Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
BuCy, then allo HSCT Partial | — | — | — | — | — | — | — | — |
4 of 4 regimens shown